NCT00786188 - Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Hot Flashes

Interventions

DRUG

Brisdelle (paroxetine mesylate)

Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.

DRUG

Sugar pill

Subjects will receive a sugar pill.

Trial Locations (10)

Philadelphia Clinical Research, Philadelphia

Virginia Women's Center, Richmond

National Clinical Research, Inc., Richmond

Hawthorne Medical Research, Inc., Winston-Salem

Hawthorne Research, Greensboro

Altus Research, Lake Worth

Anchor Research Center, Naples

Chattanooga Medical Research, LLC, Chattanooga

Women's Clinical Research Center, Seattle

North Spokane Women's Clinic Research, Spokane